INTRODUCTION
============

Lower urinary tract symptoms are not a disease that can affect survival, but are closely related to quality of life and form a huge drug market worldwide. These drugs can be prescribed not merely according to the relevant symptom, but also according to the diagnosed disease. In relation to voiding symptoms, approximately seven groups of drugs are used clinically, such as alpha-adrenoceptor antagonists, 5-alpha reductase inhibitors, antimuscarinics, phosphodiesterase type 5 (PDE5) inhibitors, beta-agonists, botulinum toxin (botox), and phytotherapic supplements \[[@b1-inj-1734928-464]\]. However, there are many trials to develop new drugs for the improved treatment of voiding symptoms. Benign prostatic hyperplasia (BPH) and overactive bladder syndrome (OAB), which are representative diseases of voiding dysfunction, are the main targets of these drugs, and tremendous efforts are underway to develop more potent and beneficial drugs for these diseases.

BPH is a conventional disease, which is characterized by hyperplasia according to aging, bladder outlet obstruction, following lower urinary tract symptoms (LUTS) \[[@b2-inj-1734928-464]\]. At present, the main drugs for treatment of BPH are alpha-adrenergic antagonists and 5-alpha-reductase inhibitors, but new drugs with different underlying mechanisms are in development \[[@b3-inj-1734928-464]\]. The size of the global BPH drug market was US \$3.2 billion in 2010 and, with an annual growth rate of 6.4%, would reach US \$5.2 billion by 2024 \[[@b4-inj-1734928-464]\]. Although the impending expiration of the patents of alfuzosin or dutasteride might be obstacles, the development of powerful drugs such as tadalafil will enable the expansion of the BPH-related drug market. Furthermore, the rapidly aging of population also supports the potential growth of this market \[[@b4-inj-1734928-464]\].

OAB is the sudden strong onset of urge to urinate, with or without urge incontinence, without a definite underlying disease \[[@b5-inj-1734928-464]\]. The history of this mainly symptom-based disease is short; it was proposed by Alan Wein and Paul Abrams in late 1997. Although the establishment of the disease category is fairly recent, and it was stigmatized as a "created disease" when first proposed, the OAB-related market has grown rapidly rate to attain a global market size of approximately US \$3 billion in 2015 and is currently growing by 1.14% annually \[[@b6-inj-1734928-464]\]. Antimuscarinic agents are still the most representative drugs for OAB, but recent treatments for OAB have shown great changes, such as the emergence of new acting types of drugs, including beta-3 adrenergic agonists, PDE5 inhibitors, and botox.

Whether it is because an increase in the number of patients that has resulted from an aging population, the emergence of new drugs arising from continuous research and academic development, or, in the worst-case scenario, the aggressive investment and marketing of the global pharmaceuticals, the drug market for voiding-related symptoms has experienced annual growth and new drugs are in continuous development to support this reality. The prospect of new drugs for the treatment BPH or OAB is important from medical or pharmaceutical viewpoints. For researchers, it can help them obtain broad and profound knowledge and insight into future treatments and keep their research focused in the right direction; for health care providers, it can enable them to make decisions about treatment regimen and energize the interventional clinical trial; and for pharmaceutical companies, it can allow proper response to the fast development and growth of the drug market, enabling aggressive investment in research that will make an ideal business plan.

In this paper, we wish to provide you with an overview of new drug development related to voiding dysfunction.

NEXT GENERATION DRUGS FOR BPH
=============================

At present, the 2 major categories about BPH medical treatment are alpha-adrenergic antagonists and 5-alpha-reductase inhibitors, but, over 60 candidate drugs are in development with multiple mechanisms of action \[[@b3-inj-1734928-464]\]. These suggested action mechanisms include super-selective alpha adrenergic antagonists, vasopressins, luteinizing hormone-releasing hormone (LHRH) antagonists, antiandrogens, PDE5 inhibitors, gonadotrophin-releasing hormone (GnRH) antagonists, flavonoids, and vaccines \[[@b7-inj-1734928-464]\].

The following summary describes drugs mainly in clinical phase 3, which are closest to clinical use \[[@b8-inj-1734928-464]\]. NX-1207, a fexapotide triflutate with selective apoptotic properties, is administered by transrectal ultrasound-guided intraprostatic injection \[[@b9-inj-1734928-464]\]. Although the injection method is somewhat difficult and invasive, it is known to effectively reduce the volume of the prostate gland and symptomatic improvement has been seen in both short-term and long-term studies \[[@b8-inj-1734928-464]\].

PRX-302 (topsalysin) is another injectable modified recombinant peptide which might be selectively activated by prostate-specific antigen (PSA), which induces prostatic cell apoptosis without damaging the surrounding tissue and nerves \[[@b10-inj-1734928-464]\]. After activation with PSA, PRX-302 is combined with other PRX-302, which induces cell apoptosis through the formation of transmembrane pores. This PSA-specific selectivity reduces the effects on nonprostate tissue and ensures for high safety of treatment \[[@b11-inj-1734928-464]\].

Elagolix is an orally administered non-peptide GnRH antagonist \[[@b12-inj-1734928-464]\]. It has a shorter acting time than other GnRH antagonists administered by a conventional subcutaneous depot injection, such as Leuplin and Goserelin, which means it has two advantages: one, it has a fast action time; two, it is easy to quit the drug in the event of appearance of adverse effects. Therefore, studies of the drug are in progress for the treatment of BPH, prostate cancer, and endometriosis \[[@b13-inj-1734928-464]\].

Udenafil is a PDE5 inhibitor that targets intracellular signaling pathways. One such example is tadalafil, which is already used clinically \[[@b14-inj-1734928-464]\]. Cyclic nucleotide monophosphate (cyclic GMP) is known to be an important mediator of the bladder and urethral vascular mechanisms. PDE5 inhibitors inhibit the degradation of the second messenger, cyclic GMP, and may play a role in the treatment of LUTS \[[@b14-inj-1734928-464]\].

Equol is a metabolite of daidzein, one of the major isoflavones in soybean. It acts as a 5-alpha-reductase inhibitor in the prostate and is known to inhibit the hormones that cause prostate cancer and male baldness \[[@b15-inj-1734928-464]\]. DA-6034 is a synthetic derivative of the flavonoid eupatilin, which is known to have antiinflammatory function \[[@b16-inj-1734928-464]\]. In addition, HCP1101, a combination of 5-alpha-reductase inhibitors, AMV110, a vaccine series, and high-dose tamsulosin are in phase III clinical trials.

Many different compounds, including ozarelix (LHRH antagonist), VA106483 (vasopressin V2 agonist), and andrine (dihydrotestosterone), which have been developed for the treatment of BPH are in the second stage of clinical development. Additionally, AKP-002 (PDE9 inhibitor), tadalafil/tamsulosin combination, and prostide (herbal extract) are in phase I clinical development. Finally, other treatments, such as cell therapy, anticancer vaccines, and contraceptives have also been studied as potential treatments for BPH \[[@b17-inj-1734928-464]\].

NEXT GENERATION DRUGS FOR OAB
=============================

Unlike BPH drug development, a number of drugs currently in development for the treatment of OAB, such as antimuscarinic agents and beta-3 agonists, which is similar to the existing therapeutics.

A representative candidate antimuscarinic agent, tarafenacin, is known to have superior selectivity to M3 in comparison with M2; it was shown to have 200 times greater selectivity \[[@b18-inj-1734928-464]\] and its characteristics include less constipation than conventional anticholinergic agents and dry mouth as the most common side effect \[[@b19-inj-1734928-464]\]. THVD-201 (Tolenix) and THVD-202 have been developed for a once daily or twice daily regimen, which is combination of tolterodine, an antimuscarinics, and pilocarpine, a modified-release muscarinic agonist \[[@b20-inj-1734928-464]\]. These drugs are designed to reduce the main adverse effects of anticholinergic drugs, such as dry mouth and constipation, which directly affect drug compliance \[[@b21-inj-1734928-464]\]. The results of clinical trials have been positive and studies are likely to be published soon. Afacifencin (MP-986), another drug of interest, which is a combination of a nonselective muscarinic antagonist and a Na+ channel blocker, blocks the afferent nerve pathway of the urinary bladder \[[@b22-inj-1734928-464]\].

Similar to a recently successfully marketed drug, mirabegron, beta-3 agonists relieve OAB symptoms through the relaxation of the detrusor muscle, the suppression of uninhibited bladder contraction, and the reduction of the afferent nerve pathway \[[@b23-inj-1734928-464]\]. This is therefore a next-generation drug of great interest. GW427353 (Solabegron), which has shown reduction of bladder contraction and proven efficacy and safety in the second phase of clinical trial, and ritobegron are in phase III clinical trials. A number of other drugs are under investigation \[[@b24-inj-1734928-464],[@b25-inj-1734928-464]\]. The combination therapy of antimuscarinics and beta-3 agonists is also an attractive therapeutic candidate; representative drugs from each series, mirabegron and solifenacin, are in phase III clinical trials \[[@b26-inj-1734928-464]\].

In addition, several medications are under investigation; some are expected to be effective, but others, though they have theoretical basis, might be ineffective. Rho-kinase pathway upregulation was found in idiopathic detrusor overactivity, bladder changes in diabetes, and obstruction to retention so the drug in relation to this pathway has been an interesting target for the inhibition of bladder overactivity \[[@b27-inj-1734928-464]\]. The vitamin D3 agonist, elocalcitol, is a RhoA/Rho kinase inhibitor and is under investigation for its effects against OAB. Although it has been reported as effective for women with OAB, further extensive studies are needed \[[@b28-inj-1734928-464]\]. Nerve growth factor (NGF) has also been suggested as a potential therapeutic medication and a possible diagnostic biomarker. However, the development of tanezumab, a humanized NGF antibody, was ceased owing to its side effects \[[@b29-inj-1734928-464]\]. Prostaglandin E~2~ was shown to activate bladder contraction via the afferent nerve through the EP1 receptor, which was attractive to the researchers as it is increased in patients with LUTS \[[@b30-inj-1734928-464]\]. However, the actual efficacy of the EP1 receptor antagonist in OAB patients in clinical trials was not satisfactory \[[@b31-inj-1734928-464]\]. Considering the action mechanism, the K+ channel opener also has been suggested as a possible treatment of OAB, but the clinical data showed no satisfactory results. In addition, cannabinoids and transient receptor potential (TRP) channel antagonists have been repeatedly investigated, but no candidates have yet emerged \[[@b32-inj-1734928-464]-[@b34-inj-1734928-464]\].

CONCLUSIONS
===========

The development of a new drug presents many opportunities: for patients to ameliorate their symptoms or disease; to reinforce the treatment effect; and for doctors and researchers to improve their treatment results and to make progress on their own research. Furthermore, it is an excellent opportunity for pharmaceutical companies to increase their market share, generate profits, and eliminate competitors. However, the development of these new drugs requires long-term effort, excessive costs, and involves a high risk of failure. Therefore, the indomitable will and continued investment and attention of the researchers, government, and pharmaceutical companies that support the research are essential.

A variety of mechanisms and new categories of drug candidates have been studied for various forms of voiding dysfunction including BPH and OAB. Many of them are close to clinical applications and commercialization, which provide hope to patients waiting for cures. It is expected that the introduction of more efficacious medications will be of significant help to the patients who have not had satisfactory experiences with the currently available treatments.
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